Psychedelics to Therapeutics - NYSE American: CYBN NEO: CYBN - April 2022
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
NYSE American: CYBN
NEO: CYBN
Psychedelics to
Therapeutics ™
April 2022
1
November 14, 2021 | WWW.CYBIN.COM
WWW.CYBIN.COM
Cautionary Statement
The information contained in this presentation has been prepared by Cybin Inc. and its affiliates (“Cybin” or the “Company”). The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available information, internally developed data and third
party information from other sources; (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company; (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company; and (d) is for
information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Where any opinion or belief is expressed in this presentation, it is based on certain
assumptions and limitations and is an expression of present opinion or belief only. The third-party information has not been independently verified. While the Company may not have verified the third-party information, it believes that it obtained the information from reliable sources and has no reason to believe it is not accurate in
all material respects. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. Cybin disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way
out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual’s circumstances are different. Readers should consult with their own
professional advisors regarding their particular circumstances. In making an investment decision, investors should not rely solely on the information contained in this presentation. The delivery of this presentation, at any time, will not imply that the information contained in the presentation is correct as of any time subsequent to
the date set forth on the cover page of the presentation or the date at which such information is expressed to be stated, as applicable. No securities commission, exchange or similar regulatory authority in Canada or the United States has reviewed or in any way passed upon the merits of this presentation, and any representation
to the contrary is an offence.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
Certain statements in this presentation constitute forward-looking information. All statements other than statements of historical fact contained in this presentation, including, without limitation, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that
include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only Cybin’s expectations,
estimates and projections regarding future events. These statements are not guaranteeing future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements.
Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or
achievements to be materially different from those expressed or implied by the forward-looking statements. Risk Factors that could cause actual results, performance or achievement to differ materially from those indicated in the forward-looking statements include, but are not limited to the following: regulatory, legislative, legal
or other developments with respect to its operations or business; general economic conditions and financial markets; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of the COVID-19 pandemic; conflicts of interest; uninsurable
risks; and litigation and other factors beyond the Company’s control. Readers are cautioned that the foregoing list and the risk factors under the heading “Risk Factors” are not exhaustive. The forward-looking information and forward-looking statements included in this presentation are made as of the date of this presentation. The
Company does not undertake an obligation to update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities law. Readers should not place undue importance on forward-looking information and should not rely upon
this information as of any other date. Third party information has not been independently verified. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information.
RISK FACTORS
There are a number of risk factors that could cause future results to differ materially from those described herein. A discussion of the principal risk factors relating to the Company’s operations and business appear in the Company’s most recently filed management's discussion and analysis and the Company's listing statement
dated November 9, 2020, which are available under the Company's profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Additional risks and uncertainties, including those that the Company is not aware of currently, or that it currently deems immaterial, may also adversely
affect the Company’s business or any investment therein. All of the forward-looking statements made in this presentation are qualified by these cautionary statements and other cautionary statements or other factors contained herein. Although management believes that the expectations conveyed by forward-looking
statements herein are reasonable based on information available on the date such forward-looking statements are made, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company
undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The forward-looking statements contained herein are presented for the purposes of assisting readers in understanding the Company’s plan,
objectives and goals and may not be appropriate for other purposes. The reader is cautioned not to place undue reliance on forward-looking statements.
CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION
To the extent any forward-looking statement in this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may
not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking statements generally, are, without limitation, based on the assumptions and subject to
the risks set out above under the heading “Cautionary Statement Regarding Forward-Looking Information” The Company’s actual financial position and results of operations may differ materially from management’s current expectations and, as a result, the Company’s revenue and expenses.
CAUTIONARY NOTE REGARDING REGULATORY MATTERS
The Company conducts research and development is focused on developing and commercializing psychedelic-inspired regulated medicines. The Canadian, United States and Ireland federal governments regulate drugs. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada), a
Schedule I drug under the Controlled Substances Act and a Schedule I controlled substance in Ireland under the Misuse of Drugs Act, 1977, 1984 and 2015, the Misuse of Drugs Regulations 2017 and the Criminal Justice (Psychoactive Substances) Act 2010. Health Canada, the Food and Drug Administration in the United States and
such similar regulatory authority in Ireland have not approved psilocybin as a drug for any indication. The Company does not deal with psychedelic substances except indirectly within laboratory and clinical trial settings conducted within approved regulatory frameworks in order to identify and develop potential treatments for
medical conditions and, further, does not have any direct or indirect involvement with illegal selling, production or distribution of any substances in jurisdictions in which it operates. No product will be commercialized prior to applicable legal or regulatory approval. For these reasons, the Company may be (a) subject to heightened
scrutiny by regulators, stock exchanges, clearing agencies and other authorities, (b) susceptible to regulatory changes or other changes in law, and (c) subject to risks related to drug development, among other things. There are a number of risks associated with the business of the Company. The Company makes no medical,
treatment or health benefit claims about the Company’s proposed products. Health Canada, the Food and Drug Administration or other similar regulatory authorities have not evaluated claims regarding psilocybin products. The efficacy of such products have not been confirmed by approved research. There is no assurance that
the use of psilocybin can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the
Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
DRUG DEVELOPMENT
Drug development involves long lead times, is very expensive and involves many variables of uncertainty. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. Every patient treated on future studies can change those
assumptions either positively (to indicate a faster timeline to new drug applications and other approvals) or negatively (to indicate a slower timeline to new drug applications and other approvals). This presentation contains certain forward-looking statements regarding anticipated or possible drug development timelines. Such
statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such
guidelines, other industry examples, and the Company’s development efforts to date.
INDUSTRY INFORMATION
This presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although the Company believes these sources to be generally reliable, such
information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. The Company has not independently verified any of the data from third party sources
referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed.
US DISCLAIMER
This presentation is not an offer of securities for sale in the United States or in any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended.
WWW.CYBIN.COM 2
Psychedelics to Therapeutics™
At Cybin, we are on a mission to engineer transformative
psychedelic therapeutics to improve patients’ mental health
and clinical outcomes
Leveraging decades of human psychedelic research to create
therapeutics that benefit patients, providers and payers:
1. Fast onset – less downtime for provider and patient
2. Short duration – less clinic time and resources needed
3. Low variability – more predictable responses projected
4. Lower dosing – efficacy with potential for reduced side effects
WWW.CYBIN.COM 3
Strong Leadership Team
Our team has deep-rooted psychedelic, pharmaceutical, regulatory and academic research expertise
with more than 400 years of combined experience in drug development
Corporate
R&D
Clinical
Academic
Advisors
• Successfully helped develop widely used drugs such as: Allegra, Sabril, Anzemet, Vaniqa, Zyprexa, Cymbalta, Neupro & Vimpat
• Overseen 60+ IND programs with FDA
• Worked on the development for the first FDA approved psychedelic compound which is covered by healthcare insurance.
WWW.CYBIN.COM 4
Corporate and Financial Highlights
• Over C$120M raised to date and • Experienced team that has Strong Intellectual Property:
well-funded to progress clinical previously brought multiple drugs • Proprietary psychedelic
trials, M&A and IP strategies to market compounds (new chemical
• Strategic shareholders including • Grown from 5 to 55 employees entities)
long-term U.S. institutional funds across 4 countries (Canada, U.S.A., • Integration with delivery
UK, Ireland) platforms
• Cash and equivalents of C$63.6m
as of December 31, 2021 • Developed 50 novel compounds • Methods of use in psychiatric
with >10 patent filings across 3 indications
• Covered by 9 research firms and patent families
inclusion in 3 psychedelic ETFs • Drug discovery pipeline of
• Completed more than 140 modified and novel
preclinical studies supporting R&D tryptamines, phenethylamines
advancement of proprietary and other compounds of
psychedelic-based molecules interest
WWW.CYBIN.COM 5
Cybin History and Key Milestones
Former Pfizer Asia President Launched the EMBARK™ USPTO grant of ‘318 patent
Acquired Boston-based
Theresa Firestone elected to Psychedelic Facilitator for deuterated DMT
Adelia Therapeutics
Board of Directors Training Program compound CYB004
R&D Collaboration Agreement Cybin lab granted DEA UK MHRA Scientific
Founded in 2019
with Greenbrook TMS to Schedule I manufacturing Advisory Meeting for
by 3 Toronto-based
establish mental health centers license CYB003
co-founders
of excellence
Dec 2019 Nov 2020 Dec 2020 Jan 2021 Jun 2021 July 2021 Aug 2021 Oct 2021 Nov 2021 Feb 2022 Mar 2022
Investigational deuterated
Began trading on Former FDA Psychiatry psilocybin analog CYB003 shows
NEO exchange under ticker Director Dr. Laughren joins positive preclinical data including Successful completion
‘CYBN’ Clinical Advisory Board significant advantages of CYB003 IND-
over oral psilocybin enabling preclinical
studies
Kernel Flow partnership, a Uplisted to NYSE
wearable, quantitative American, began trading The Chopra Foundation
neuroimaging technology under the ticker 'CYBN' Announces Partnership
with Cybin
WWW.CYBIN.COM 6
Timeline for Developing Psychedelics to Therapeutics
Q1 2022 Q2 2022 Q3 2022 Q4 2022
✓ Completed • CYB003 IND filing for • Initiate CYB003 • Potential
CYB003 preclinical Phase 1/2a MDD trial Phase 1/2a MDD CYB003 interim
studies patient study data readout
✓ Preclinical data
✓ CYB003 Scientific announced for • Initiate CYB004
Advice meeting CYB004 vs DMT human pilot
with UK MHRA study
• Submit CYB004
✓ Initiated EMBARK regulatory filing for
Phase 2 IIT study pilot study
✓ Initiated Kernel • Late Q2: preclinical
Flow feasibility data expected for
study CYB005
• Nominate CYB005 as
partnering candidate
WWW.CYBIN.COM 7
Unmet Need for Treatment of Mental Health Disorders
World Health Organization States That Mental Health Disorders Affect
More Than 900M People Globally (1)
Depression Alcohol Use Disorder Anxiety Disorders
CYB003 CYB003 CYB004
800,000 95,000 5.1% to 11.9%
Deaths due to suicide globally every year (1) Estimated alcohol related deaths in the General anxiety disorder lifetime
U.S. (3) prevalence in the United States (4)
Up to 85% 3M 3% to 7%
Between 76% and 85% of people in low-
and middle-income countries receive no Global deaths attributed to alcohol Social anxiety disorder lifetime prevalence
treatment for their disorder (1) consumption (3) in the Unites States (4)
The global direct and indirect economic costs from mental disorders is US$2.5 Trillion (2)
(1) https://www.who.int/news-room/fact-sheets/detail/depression (3) https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-use-disorder & https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-facts-and-statistics
(2) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007565/ (4) Ruscio et al. Psychol Med. 2008;38(1):15.
WWW.CYBIN.COM 8
Psychedelics Provide Therapeutic Benefits with Potentially
No Abuse or Addictive Characteristics
Source J. M. Fish (Ed.),Drugs and Society: U.S. Public Policy,
pp.149-162, Lanham, MD: Rowman & Littlefield Publishers Neuropharmacology. 2018 November ; 142: 143–166.
Study Name Acute toxicity of drugs versus regulatory status.
Gable, R. S. (2006)
Treatment Episode Datasets (TEDS): Rate of Various Drugs as the Primary
Data Substance of Abuse Among Persons 12 Years and Older, 2005–2015
Primary Substance 2010 2011 2012 2013 2014 2015
Total (n) 1,932,524 1,936,278 1,834,591 1,762,015 1,639,125 1,537,025
Hallucinogens (n) 1,791 1,998 2,155 2,177 1,899 1,917
0.1% 0.1% 0.1% 0.1% 0.1% 0.1%
Opiates (n) 443,405 486,729 488,038 507,989 501,680 526,686
22.9% 25.1% 26.6% 28.8% 30.6% 34.3%
Cocaine (n) 158,780 152,349 126,371 106,594 88,623 74,710
8.2% 7.9% 6.9% 6.0% 5.4% 4.9%
Alcohol* (n) 782,764 759,017 709,891 654,808 591,404 521,089
40.5% 39.2% 38.7% 37.2% 36.1% 33.9%
• Alcohol only or with a secondary drug
Source: (Substance Abuse and Mental Health Services Administration, 2017a)
Conclusions: Certain drugs have more severe consequences of use than others, Conclusions: (1) psilocybin has an abuse potential appropriate for CSA scheduling if
Result can be more addictive, harmful to the body or even lethal. However, legality of a approved as medicine; (2) psilocybin can provide therapeutic benefits that may
drug does not consistently predict severity of consequences. Marijuana is illegal in support the development of an approvable new drug application (NDA) but further
many locations and yet is considered more innocuous than many other substances studies are required which this review describes; (3) adverse effects of medical
(Gable, 2006). Conversely, some of the most harmful drugs, such as opioids, alcohol psilocybin are manageable when administered according to risk management
and tobacco are legal and used widely in many countries, including the U.S.A. Figure approaches; and (4) although further study is required, this review suggests that
1 displays the most dangerous drugs, based on plotting the dependence potential placement in Schedule IV may be appropriate if a psilocybin-containing medicine is
of the drug versus the active/lethal dose. approved.
WWW.CYBIN.COM 9Academic Studies Demonstrate Efficacy of Psychedelic Treatment
JAMAPsychiatry | Original Investigation | November 4, 2020
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
A Randomized Clinical Trial
Alan K. Davis, PhD; Frederick S. Barrett, PhD; Darrick G. May, MD; Mary P. Cosimano, MSW; Nathan D. Sepeda, BS; MatthewW. Johnson, PhD;
Patrick H. Finan, PhD; Roland R. Griffiths, PhD
Data: 17 participants (71%) at week 1 and 17 (71%) at week; 4 had a clinically
significant response to the intervention (50% reduction in GRID-HAMD
score), and 14 participants (58%) at week 1 and 13 participants (54%) at
week 4 were in remission (7 GRID-HAMD score)
Results: Psilocybin with therapy is efficacious in treating MDD, thus extending
the results of previous studies of this intervention in patients with
cancer and depression and of a non-randomized study in patients with
treatment-resistant depression. *Effect sizes in well-controlled studies in MDD are traditionally very small,
ranging from 0.17 to 0.57
Other
Studies:
COMPASS news December 01, 2021
Positive results from phase IIb trial of
investigational COMP360 psilocybin therapy
for treatment-resistant depression
WWW.CYBIN.COM 10Psychedelic Molecules of Interest
Psychedelic Class Chemical Structure & Molecule Primary Target Predominant Route of Administration
Properties: Psilocybin is typically taken orally and
dephosphorylated to psilocin in the intestinal lining and
liver before entering blood circulation.
Tryptamine Serotonin Receptor Pharmacokinetics: Onset of psychoactive effects begin
5-HT2A within 20-40 minutes after ingestion and last between
2-4 hours depending on dose, species and individual
metabolism. Within 6–8 hours, the subjective drug
effects will have mostly disappeared.
Properties: DMT is not bioavailable when orally ingested
due to rapid elimination by monoamine oxidase A
(MAO-A) in the body. IV or inhalation are the traditional
Tryptamine Serotonin Receptor routes of administration.
5-HT2A
Pharmacokinetics: The time course of DMT delivered via
IV is brief. The onset is very rapid, with full effects noted
within 2 minutes and subjective effects usually fully
resolved within 20–30 minutes.
Phenethylamine class: A very large class of molecules
derived from a base benzene ring with an amino group
Serotonin Receptors & attached through two-carbon.
Phenethylamines Transport Sites
Derivatives: Includes 2C-B, MDMA, mescaline,
amphetamine analogues such as DOI and DOM, and
Phenethylamine
25I-NBOMe.
In addition to the molecules themselves, there are two important factors in the psychedelic treatment regimen:
1) Psychological support before, during and after the treatment session
2) Dosing regimen
WWW.CYBIN.COM 11Research and Development Pipeline
PROGRAM1 DISCOVERY PRECLINICAL PHASE I PHASE 2 PHASE 3 REGISTRATION
Major Depressive Disorder Mid-2022: Initiate Phase 1/2a study
CYB003-Deuterated Psilocybin Analog
Alcohol Use Disorder
CYB003-Deuterated Psilocybin Analog
Anxiety Disorders Q3 2022: Initiate pilot study
CYB004-Deuterated Dimethyltryptamine (DMT)
Neuroinflammation
CYB005-Phenethylamine Derivative
Mental Distress in Healthcare Workers2 Phase 2 IIT study underway
EMBARK–psilocybin for mental distress in frontline healthcare workers
Psychedelic Effects On Brain3 Feasibility study underway
Kernel Flow-Neuroimaging Technology
NOTES:
1) Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Cybin is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to
obtain psilocybin and other analogues.
2) Phase 2 investigator-initiated study being conducted by Dr. Anthony Back, professor of medicine (oncology) at the UW School of Medicine and co-funded by Cybin.
3) Cybin-sponsored Phase 1 feasibility study evaluating Kernel’s Flow Technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.
WWW.CYBIN.COM 12CYB003: Deuterated Psilocybin Analog
Indication: Targeting major depressive
disorder (MDD) and alcohol use CYB003 Features
disorder (AUD) with potential for reduced side
effects associated with classical psilocybin Replaced one or
more hydrogen
MoA: 5-HT2A-R agonist atoms with
Current status: IND filing planned for Q2’22; deuterium, a
Phase 1/2a patient trial initiation in mid-2022 heavier stable
isotope
Completed IND-enabling development:
Reduced
• Preclinical package demonstrating
pharmacokinetic
psychedelic activity to support clinical
variability
development (efficacy and
safety)according to FDA guidelines Improved
• Optimized pharmacokinetic (PK) profile bioavailability
• Used to predict efficacious and safe Development of
human doses new chemical
entity
WWW.CYBIN.COM 13CYB003 provides therapeutic advantages over oral psilocybin
Proprietary molecules, like CYB003, provide improved therapeutic properties over their natural counterparts
Properties Psilocybin CYB003 Potential benefits for patients
Psychedelic effect ✓ ✓ Therapeutic potential
Safer dosing and more predictable
Low variability in plasma levels X ✓ patient outcomes
Fast onset of action Less down time in clinic and faster
X ✓ onset of effects
Short total duration of action X ✓ Shorter clinic days and costs
Therapeutic effects at lower doses,
Rapid brain distribution X ✓
potentially better tolerability
Natural Proprietary
Source: Company data based on preclinical studies
WWW.CYBIN.COM 14CYB003 has potential for less variability vs. classic psilocybin
40 180
CYB003
35 Psilocybin
150
Active Agent Between Subjects
50%
Percent Plasma Variability of
Plasma Concentration of
30
Active Agent (ng/ml)
120
25
20 90
15
60
10
30
5
0 0 *
0 1 2 3 4
Psilocybin CYB003 Time (Hours)
Less variability with CYB003 could translate to safer dosing and more predictable patient outcomes
Data is based on plasma concentration profiles following administration of psilocybin or CYB003 to animals
WWW.CYBIN.COM 15CYB003 may potentially reduce clinic time for patients
by 50% v. classic psilocybin
Psilocybin Psilocybin
CYB003 50% CYB003 50%
Time (Hours) 0 0.2 0.4 0.6 0.8 1 Time (Hours) 0 1 2 3 4
CYB003 onset of action is 2X as fast as oral CYB003 duration effects are cut in half
psilocybin compared to oral psilocybin
Data is based on plasma concentration profiles following administration of psilocybin or CYB 003 to animals
WWW.CYBIN.COM 16CYB003 has potential for less side effects v. classic psilocybin
12
Brain to Plasma Ratio of Active Agent
42%
10
8
Improved brain to plasma
ratio could result
6 in therapeutic effects at
lower doses and potential
4 for less side effects
2
0
Psilocybin CYB003
Data is based on plasma concentration profiles following administration of psilocybin or CYB 003 to animals
WWW.CYBIN.COM 17CYB003 Clinical Path to Proof-of-Concept
Key Features: The Phase 1/2a trial design allows us to:
• Randomized, double-blind, placebo- • Rapidly escalate into the effective dose
controlled Phase 1/2a trial design range for MDD patients
• Moderate to severe MDD patients will all • Allows for the characterization of the full-
receive 2 administrations (placebo/active; dose response curve
active/active) • Provides PK and safety data in a large
• Response/remission assessed at Week 3 number of exposures (almost double
(after single dose) and at Week 6 (after normal first-in-human study)
second dose) • Evaluate more than one administration to
identify greatest efficacy
• Assess rapid onset of antidepressant effect
on the day of dosing (using MADRS) • Evaluate effect of CYB003 on patients
continuing treatment with antidepressant
• Safety and PK data generation
medication
Initiation of Phase 1/2a study is expected in mid-2022
WWW.CYBIN.COM 18CYB004: Deuterated Dimethyltryptamine (DMT)
Indication: Targeting anxiety disorders with
improved control via inhalation CYB004 Features
MoA: 5-HT2A-R agonist
Potential to
Scientific Rationale: enhance
✔ DMT has agonistic actions on a range durability
of 5-HT receptors
✔ Efficacy demonstrated in a range of
Reduced dose
observational and real-world studies in
for better safety
depression, anxiety and substance use
disorders
Potential to
✔ Inhalation provides a similar dose profile
increase duration
as IV DMT and is less invasive
of effect
IP: U.S. patent granted by USPTO
that covers new chemical entity claims for Potential to
CYB004 until 2041 alleviate negative
Current status: Regulatory filing for experiences
pilot study anticipated in Q2 2022 v. DMT
WWW.CYBIN.COM 19CYB004 Demonstrates Positive Preclinical Data
2000% 41% 300%
Improved bioavailability Longer duration of effect
Improved bioavailability
compared with oral DMT, compared with IV DMT, indicating
compared with inhaled DMT,
which is known to have limited potential to extend therapeutic
which may support lower dosing
to no oral bioavailability window
Data is based on preclinical studies of CYB004 in animal model
WWW.CYBIN.COMCYB005: Phenethylamine Derivative - Partnering
Indication: Potential to target
neuroinflammation in neurological and CYB005 Features
psychiatric conditions
Psychoactive
MoA: 5-HT2A-R agonist lead candidate compound that
activates CNS
Scientific rationale:
• Highly potent 5-HT2A agonist Long duration of
action
• Excellent brain penetration and limited
peripheral exposure
Favorable
• Induces strong head twitch response
in vitro toxicity
in vivo
data
• Extended duration to allow for
infrequent dosing
Good oral
Development strategy: bioavailability
Potential partnership opportunity
WWW.CYBIN.COM 21Why Cybin?
Our Company:
✓ Experienced management team across pharmaceuticals, psychedelics, regulatory,
and capital markets with proven track record bringing multiple drugs to market
✓ Multiple active drug programs targeting mental illness, addiction, neuroinflammation
and psychiatric disorders
✓ Well capitalized to move drug development programs forward
Our Approach:
✓ Strong and growing IP portfolio across 3 patent families to support clinical trials,
M&A, and IP strategies
✓ Strong preclinical pipeline of 50+ novel psychedelic-based molecules
✓ 50 partnerships with world-class scientists and CROs support R&D programs
Our Future:
✓ IND filing for first Phase 1/2a study of deuterated psilocybin analog (CYB003) in Q2’22
✓ Pilot study supporting CYB004 program initiating in Q2’22
Notes:
▪ Forward-looking statements are subject to various risks and assumptions. See “Cautionary Notes and Forward-Looking Statements” on page 2 of this presentation.
▪ Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Cybin is working. There are multiple risk factors regarding the ability to successfully commercially
scale a chemically synthesized process to obtain psilocybin and other analogues.
▪ Certain statements regarding psilocybin have not been evaluated by the Food and Drug Administration, Health Canada, or other similar regulatory authorities, nor has the efficacy of psilocybin been confirmed by approved research. There is no assurance that any of the
Company’s compounds will be used to diagnose, treat, cure or prevent any disease or condition and robust scientific research and clinical trials are needed.
WWW.CYBIN.COM 22THANK YOU
NYSE American:CYBN
Contact: ir@cybin.com NEO:CYBN
WWW.CYBIN.COM 23You can also read
